$1.64 was the close today. The following is from Seeking alpha by Jamie Moye. Geron has telomerase licensing deals with Merck and with Sienna Cancer Diagnostics. The comany has no debt and enough cash in the bank to run its trials and research for the next two years. Without any FDA approvals placing a value on its products, and thus the potential value of its stock, it's truly like throwing knives in the dark, but the potential value is so astronomical that this stock must have the best risk reward ratio in the field of biotech. That was written June 12, 2009. Now in less then 9 months we will know if Geron has a future and if I'm broke or rich.
Good luck in this rigged casino,
No comments:
Post a Comment